Research Article

Anti-Inflammatory Effects of Heat-Processed *Artemisia capillaris* Thunberg by Regulating IκBα/NF-κB Complex and 15-PGDH in Mouse Macrophage Cells

Akhtar Ali,1 Junsik Lim,2 En Hyung Kim,3 Jong-Hyun Lee,4 Shin Seong,5 and Wonnam Kim1

1Cnh Center for Cancer Research, Gangnam-gu, Seoul 06154, Republic of Korea
2Division of Pharmacology, College of Korean Medicine, Semyung University, Jecheon 27136, Republic of Korea
3Department of Dermatology, Bundang Jesaeng General Hospital, Seongnam, Gyeonggi 13590, Republic of Korea
4Department of Natural Medicine, College of Pharmacy, Dongduk Women’s University, Seongbuk-gu, Seoul 02748, Republic of Korea
5Soram Korean Medicine Hospital, Gangnam-gu, Seoul 06154, Republic of Korea

Correspondence should be addressed to Wonnam Kim; wonnam_kim@semyung.ac.kr

Received 5 August 2020; Accepted 26 May 2021; Published 7 June 2021

Academic Editor: Li Zhang

Growing evidence suggests that dietary nutrients in herbs and plants are beneficial in improving inflammatory disorders. *Artemisia capillaris* Thunberg (AC) is a traditional herbal medicine widely used in East Asia to treat pain, hepatotoxicity, and inflammatory disorders. Heat processing is a unique pharmaceutical method used in traditional herbal medicine to enhance the pharmacological effects and safety of medicinal plants. This study demonstrates the anti-inflammatory effects of heat-processed AC (HPAC) in lipopolysaccharide- (LPS-) treated mouse macrophage cells. HPAC reduced LPS-induced inflammatory mediators such as IL-6, IL-1β, TNF-α, NO, and PGE2 in RAW 264.7 cells. Interestingly, 15-PGDH appears to play a pivotal role rather than COX-2 and mPGES-1 when HPAC regulated PGE2 levels. Meanwhile, HPAC showed anti-inflammatory effects by blocking IκBα phosphorylation and NF-κB nuclear translocation. Also, we found that HO-1 upregulation was mediated by the mitogen-activated protein kinase (MAPK) pathways in HPAC-treated RAW 264.7 cells. And, in RAW 264.7 cells challenged with LPS, HPAC restored HO-1 expression, leading to NF-κB inhibition. Through further experiments using specific MAPK inhibitors, we found that, in response to LPS, the phosphorylated IκBα and activated NF-κB were attenuated by p38 MAPK/HO-1 pathway. Therefore, HPAC targeting both the IκBα/NF-κB complex and 15-PGDH may be considered as a potential novel anti-inflammatory agent derived from a natural source.

1. Introduction

Inflammation is a defensive mechanism which acts by removing harmful stimuli such as pathogens, damaged cells, and toxic compounds. It consists of several processes mediated by activated inflammatory and immune cells, including macrophages and monocytes, and incorporates a complex series of reactions regulated by cytokines, growth factors, nitric oxide (NO), and prostaglandins (PGs) produced by active macrophages [1, 2]. However, uncontrolled acute inflammation may become chronic, contributing to numerous chronic inflammatory diseases, including arthritis, autoimmune diseases, atherosclerosis, and chronic hepatitis [3, 4]. There is growing evidence that plant foods rich in dietary nutrients are beneficial by inhibiting inflammatory mediators and treating diseases related to such factors [5, 6]. Omega-3 fatty acid which is found in several types of nuts and seeds has been reported to protect against
Evidence-Based Complementary and Alternative Medicine

2. Materials and Methods

2.1. Materials and Chemicals. Dulbecco's modified Eagle's medium (DMEM), penicillin-streptomycin, and fetal bovine serum (FBS) from Thermo Fisher (Carlsbad, CA, USA); dimethyl sulfoxide (DMSO), lipopolysaccharide (LPS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT), and dexamethasone (DXM) from Sigma-Aldrich (Saint Louis, MO, USA); SB203580 (p38) inhibitor and PD98059 (ERK inhibitor) from Tokyo Chemical Industry (TCI, Tokyo, Japan) and SP600125 (JNK inhibitor) from Sigma-Aldrich (Saint Louis, MO, USA); antibody against NF-κB p65 from Abcam (Burlingame, CA, USA); specific antibodies used against iNOS, COX-2, HO-1, ERK, JNK, p38, IκBα, p-ERK, p-JNK, p-p38, p-IκBα, and β-actin from Cell Signaling Technology (Beverly, MA, USA); antibodies against mPGES-1 and 15-PGDH from Cayman Chemicals (San Diego, CA, USA) were used.

2.2. Preparation of Heat-Processed Artemisia capillaris Thunberg Extract. Dried AC was purchased from Sunil-crude drugs (Hongcheon, Korea). The procedure to prepare HPAC follows a previous report with modification [35]. AC was soaked in 30% EtOH for 30 min. AC was roasted in a convection oven (JSOF-150, JS Research Inc., Korea) for 1 h 20 min in 200°C. To prevent the herb from burning, the herb was turned over every 5 min while roasting. HPAC with 2 L of 30% ETOH was boiled for 2 h in 100°C, following filtration and evaporation. The lyophilized HPAC was successively extracted with a yield (w/w) of 8.22%. The voucher specimen (HPAC: BON190527.145) was stored at the herbarium of Korean Medicine at Semyung University. The lyophilized powders were solubilized and diluted with DMSO before treatment.

2.3. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis. The constituents of the HPAC extract were evaluated using GC-MS analysis. GC-MS analysis was performed on an Agilent 6890N GC system interfaced with a Leco Pegasus IV Time of flight Mass Spectrometer. The electron energy was ~70 eV, and the ion source temperature was 220°C. Each sample (1 μL, dissolved in MeOH) was injected in split mode (10:1) at 280°C and separated through a capillary column of DB-5MS (30 × 0.25 × 0.25) (Agilent J&W column). The initial oven temperature was 30°C, which was increased to 300°C at 10°C/min. Carrier gas (Helium) flow was 0.8 mL/min.

2.4. Cell Culture. RAW 264.7 cells were obtained from Korean Cell Line Bank (KCLB) and incubated in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 μg/mL streptomycin under an atmosphere containing 5% CO2 at 37°C in an incubator.

2.5. MTT Cytotoxicity Assay. The cytotoxicity of HPAC on RAW 264.7 cells was assessed via colorimetric MTT assay. RAW 264.7 cells were grown at a density of 1 × 10^4 cells per well in 96-well plate. After 24 h, cells were then treated with different concentrations of HPAC and incubate for 24 hr. Following treatment, 20 μL of MTT (5 mg/mL) solution was added to each well and further incubated for 4 h at 37°C. Next, the media (containing MTT solution) were removed from each well and 100 μL of DMSO was added to each well to dissolve the resulting formazan crystals. Finally, the plate was smoothly agitated for 10 min on a shaker, and the absorbance was then measured at 570 nm using a microplate reader (BioTek, Winooski, VT, USA). The results were shown as relative cell viability referred to as control (equal to 100%).
2.6. Measurement of Nitric Oxide (NO) Production. NO concentration in the cell culture medium was determined using a colorimetric assay based on the Griess reaction. To measure NO secretion, RAW 264.7 cells were seeded in 96 well plates, 5 × 10^4 cells per well. After 24 h, cells were pretreated with different concentrations of HPAC for 2 h and then stimulated with 1 μg/mL of LPS for an additional 24 h. After LPS stimulation, a cell culture medium was collected to measure the amount of NO using the Griess reagent. In brief, 50 μL of Griess reagent was added to an equal volume of cell culture medium in a 96-well plate and the plate was smoothly agitated for 10 min on a shaker at room temperature. Finally, the concentration of nitrite was calculated from a standard curve of known concentrations of sodium nitrite dissolved in DMEM.

2.7. Determination of IL-6, IL-1β, TNF-α, and PGE2. RAW 264.7 cells were plated in a 24-well plate at a density of 1 × 10^5 cells/well and incubated overnight. The cells were pretreated with different concentrations of HPAC for 2 h and then challenged with LPS for another 24 h. The supernatants were then centrifuged at 12,000 rpm at 4°C for 5 min to discard cell debris and the remnant media was collected. The levels of IL-6, TNF-α, and IL-1β were measured by enzyme-linked immunosorbent assay using ELISA kit (Invitrogen, Carlsbad, CA, USA) and PGE2 were analyzed using ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

2.8. Extraction of Nuclear and Cytosolic Fraction. Cytoplasmic and nuclear extracts were prepared using a Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Rockford, IL, USA) following the manufacturer’s instructions. Briefly, the RAW 264.7 cells were seeded in 6-well plates at a density of 5 × 10^5 cells/well and incubated for 24 h. Next, the cells were pretreated with different concentrations of HPAC for 2 h and then stimulated with LPS for another 2 h. The cells were then harvested with PBS and centrifuged. Next, an ice-cold cytoplasmic protein extraction solution was added and centrifuged to separate the cytoplasmic extract. Then, the cytoplasmic extract was transferred to clean prechilled tubes and the pellets produced were prepared for nuclear extraction by adding ice-cold nuclear protein extraction solution.

2.9. Western Blotting. Cells were lysed in RIPA lysis buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)) with protease inhibitor cocktail (Roche, Mannheim, Germany). The protein concentration was determined using the bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL, USA). Total protein lysates were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were then blocked for 1 h at room temperature in 5% skim milk, followed by an overnight incubation at 4°C with a specific primary antibody. The next day, the membranes were washed and incubated for an additional 1 h with HRP-conjugated secondary antibody (1:5000) at room temperature after thoroughly washing three times with TBST. Bands were detected by ECL (LPS Solution, Daejeon, Korea), and band intensities were quantified using ImageJ gel analysis software.

2.10. Statistical Analysis. Statistical calculations were done in GraphPad Prism version 5. Results are presented as means ± SEM. Data were analyzed by one-way ANOVA followed by post hoc Tukey’s test. p < 0.05 indicates statistical significance.

3. Results

3.1. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis. HPAC extract was analyzed using a GC-MS and compared with standards from the library database. Butyro lactone (1), dihydro-3-methylene-2,5-furandione (2), catechol (3), hydroquinone (4), 2-methoxy-4-vinylphenol (5), 2,6-dimethoxy-phenol (6), scoparone (8), 9-octadecenoic acid (9), 2-hydroxy-1-(hydroxymethyl)ethyl ester hexadecanoic acid (10), and 2,3-dihydroxypropyl ester octadecanoic acid (11) were observed in HPAC extract (Figure 1).

3.2. Cell Viability and Cytokine Production. RAW 264.7 cells were treated with different concentrations of HPAC (5 μg/mL to 500 μg/mL) and cell viability was performed by MTT assay. After HPAC treatment, significant cell toxicity was observed at 400 μg/mL, and lower concentrations (5 μg/mL to 200 μg/mL) did not show significant changes (Figure 2(a)). Therefore, the concentrations of HPAC ranging from 50 μg/mL to 200 μg/mL were employed for further study. Dexamethasone (DXM), a classic steroidal anti-inflammatory and immunomodulatory drug, was included as the positive control in the study [36]. TNF-α, IL-6, and IL-1β cytokines play essential roles in inflammatory responses; thus, we investigated whether HPAC could inhibit secretion of these cytokines in macrophages stimulated by LPS. After LPS activation, the results show that IL-6 (147-fold), IL-1β (68-fold), and TNF-α (93-fold) levels significantly increased compared to control (Figures 2(b)–2(d)). HPAC treatment suppressed the production of these cytokines in a dose-dependent manner; however, significance was achieved only at 200 μg/mL (Figures 2(b)–2(d)). The levels of IL-6 (0.4-fold), IL-1β (0.5-fold), and TNF-α (0.8-fold) changed significantly in the HPAC-treated group (200 μg/mL) compared to the LPS-treated group. After LPS stimulation, the HPAC-treated group demonstrated a lesser effect on inhibiting TNF-α and IL-1β production compared to the DXM-treated group (Figures 2(c) and 2(d)). However, HPAC treatment showed stronger IL-6 inhibition in comparison to DXM at 200 μg/mL (Figure 2(b)). These results indicate that HPAC inhibits the LPS-induced release of proinflammatory cytokines in RAW 264.7 cells.

3.3. HPAC Regulates NF-κB Nuclear Translocation. NF-κB has been reported to be a positive regulator of numerous inflammatory mediators and proinflammatory
cytokines [37, 38]. So we hypothesized that the inhibitory effect of HPAC on cytokine secretion may be likely via NF-κB regulation. To elucidate the inhibitory effect of HPAC on NF-κB nuclear expression, RAW 264.7 cells were pretreated with the indicated concentrations (100 and 200 μg/mL) of HPAC for 2 h and then stimulated with LPS for 2 h. Results showed that the protein levels of NF-κB p65 in the nuclear fraction significantly increased in the LPS-treated group (40-fold), whereas HPAC treatment inhibited the nuclear translocation of NF-κB p65 (Figures 3(a) and 3(b)). (Here nuclear expression of NF-κB p65 in HPAC-treated cells (200 μg/mL) showed a 0.7-fold change compared to LPS-treated cells (Figure 3(b)).

NF-κB transcriptional activity is suppressed by a stable IκB/NF-κB complex whereas activated IκB kinase, by inflammatory stimulus, phosphorylates IκB leading to ubiquitination and its degradation [39]. To explore how HPAC prevents LPS-induced NF-κB activation, we investigated the inhibitory effect of HPAC on the phosphorylation of IκBα, which led to NF-κB activation. Our data show that LPS strongly phosphorylated IκBα, by a 19-fold change, compared to control. And HPAC treatment attenuates the increased phosphorylation of IκBα, by 0.8- and 0.3-fold, compared to LPS treatment (Figures 3(c) and 3(d)). These results suggest that HPAC reduced NF-κB nuclear translocation by inhibiting IκBα phosphorylation.

3.4. HPAC Regulates NO and PGE2 Production. NO is a vital proinflammatory mediator, and excessive NO production is involved in the pathogenesis of many inflammatory diseases [40, 41]. Activation of iNOS, mainly regulated by NF-κB, increases NO production [42, 43]. Therefore, we examined the inhibitory effect of HPAC on LPS-induced iNOS and NO levels in RAW 264.7 cells. As shown in Figures 4(a) and 4(b), iNOS

![Figure 1: GC-MS analysis of HPAC. (a) GC-MS chromatograms of HPAC. (b) Structure of candidate compounds by GC-MS. The HPAC extract contains lactones (1, 2), phenolics (3–8), fatty acids (9), and fatty acids ester (10, 11).](image-url)
expression was remarkably elevated by LPS stimulation and HPAC significantly attenuated the protein expression of iNOS in a dose-dependent manner. Furthermore, HPAC achieved the strongest inhibition (0.04-fold) at 200 μg/mL, which was more significant than DXM (0.5-fold) (Figure 4(b)). Next, NO production was analyzed by measuring the accumulation of nitrites in the supernatants using Griess assay. HPAC treatments significantly inhibited LPS-induced NO production dose-dependently (Figure 4(c)).

PGE2 has been implicated in various biological actions, such as pain sensation and inflammatory condition [44]. COX-2 and mPGES-1 are functionally coupled and considered as the primary enzymes for the inflammatory PGE2 generation [45]. Although the positive control DXM showed significant inhibitory effects against COX-2 expression, HPAC had no effect in decreasing COX-2 and mPGES-1 expression (Figures 4(a), 4(d), and 4(e)). 15-PGDH is identified as a catabolizing enzyme that converts PGE2 into its inactive product [45]. HPAC treatment showed a dose-dependent increase in 15-PGDH expression and the maximum effect was achieved at 200 μg/mL (1.6-fold) (Figures 4(a) and 4(f)). Taken together, these results indicate that the inhibitory effect of HPAC on PGE2 production is mediated by 15-PGDH upregulation (Figure 4(g)).

3.5. HPAC Regulates HO-1 via MAPK Signaling. HO-1 is an important component of the cellular defense against inflammation [46], we further examined whether HPAC could induce HO-1 expression. Our data show that by treating RAW264.7 cells at a fixed concentration of 200 μg/mL, HO-1 was expressed as early as 2 h and continuously increased until 8 h, after which the expression was reduced (Figures 5(a) and 5(b)). Also, in accordance with the different concentrations of HPAC, HO-1 expression significantly increased dose-dependently (Figures 5(c) and 5(d)). Next, we investigated the underlying mechanism of HO-1 induction by HPAC treatment. MAPK family signaling cascades have been reported to induce HO-1 expression [47–49]. (Q_hence, in the current study, the effects of HPAC on phosphorylation levels of MAPKs including JNK, p38, and ERK were analyzed. While phosphorylation of p38, ERK, and JNK MAPKs increased by HPAC treatment, significance only occurred at the highest concentration (Figures 5(e)–5(g)). The significant upregulation of p38, ERK, and JNK at 200 μg/mL was in parallel with HO-1 induction (Figure 5(d)). In addition, HPAC treatment activated p38 (3.8-fold) to a greater extent than ERK (2.8-fold) and JNK (2.4-fold) (Figures 5(e)–5(g)). To further verify the
involvement of MAPK pathway in the upregulation of HO-1 expression by HPAC, the effects of MAPK specific inhibitors, p38 (SB203580), ERK1/2 (PD98059), and JNK (SP600125), were analyzed. As indicated in Figures 5(h) and 5(i), treating the cells with HPAC significantly increased the level of HO-1 by 10-fold, whereas SB203580, PD98059, and SP600125 administration attenuated HO-1 expression by 0.7-, 0.8-, and 0.4-fold, respectively. Taken together, these results indicate that the upregulation of HO-1 expression by HPAC was mediated via the MAPK pathway in RAW 264.7 cells.

3.6. HPAC Regulates IκBα/NF-κB Pathway by HO-1 Activation. Our results found that HPAC upregulates HO-1 expression via activating MAPK. Furthermore, HPAC prevented NF-κB p65 nuclear translocation by suppressing IκBα phosphorylation. Previously, it has been reported that HO-1 inhibits NF-κB nuclear translocation [50, 51]. To clarify, whether HPAC inhibits NF-κB p65 nuclear translocation via inducing HO-1 expression through activating MAPK, the effect of MAPK inhibitors on HPAC-induced HO-1 expression and IκBα phosphorylation was evaluated in LPS-challenged cells. Despite the fact that SB203580, PD98059, and SP600125 reversed the HPAC-induced HO-1 expression (Figures 5(h) and 5(i)), interestingly, SB203580 and SP600125 significantly reversed the HPAC-mediated HO-1 upregulation in LPS-treated condition. However, PD98059 had no effect on HO-1 expression in the LPS-treated condition (Figures 6(a)–6(c)). Furthermore, only SB203580 (but not PD98059 and SP600125) markedly enhanced the repressed IκBα phosphorylation by HPAC treatment in the LPS-treated condition. As shown in Figures 3(a) and 3(b), HPAC prevented NF-κB p65 nuclear translocation. In contrast, the nuclear accumulation of NF-κB p65 was rescued by SB203580 and SP600125 (Figures 6(d) and 6(e)). Together, these results suggest that p38 MAPK-dependent HO-1 may play a functional role in regulating NF-κB by HPAC under inflammatory conditions.

4. Discussion

Processing, also known as Paozhi in Chinese or Poje in Korean, is a traditional pharmaceutic method involving techniques such as stir-frying, stewing, boiling, and steaming [52]. Before clinical application, different processing techniques are used to reduce and prevent toxicity and to induce effectiveness via guidance and concentration [53]. Studies show that processing reduced cytotoxicity of Gardenia jasminoides Ellis. and Xanthium sibiricum Patr. extracts
Figure 4: Effect of HPAC on NO and PGE$_2$ production. RAW 264.7 cells treated with indicated concentrations of HPAC for 2 h followed by LPS for 24 h. (a) Western blot analysis of iNOS, COX-2, mPGES-1, 15-PGDH, and β-actin. Quantitative analysis of (b) iNOS, (d) COX-2, (e) mPGES-1, and (f) 15-PGDH expression relative to β-actin. (c) NO and (g) PGE$_2$ production were determined by Griess assay and ELISA, respectively. DXM was used as a positive control. The data are presented as means ± SEM (n = 3). **$p < 0.001$ versus control group, * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ versus LPS group.

Both HPAC and AC treatment showed significant cytotoxicity at 400 and 500 μg/mL, but HPAC was considerably less toxic (Supplementary Figure 1).

Inflammation is a complex biological process regulated by inflammatory mediators such as TNF-α, IL-1β, IL-6, NO, and PGE$_2$. The excessive production of proinflammatory cytokines is generally recognized to play key roles in the development of inflammatory diseases [55, 56]. DXM is a potent synthetic corticosteroid that exhibits anti-inflammatory and immunosuppressive effects [36]. DXM is widely used for the treatment of pneumonia, bronchiolitis, and rheumatoid arthritis [57–59]. The DXM-treated group was considered as the positive control. Numerous studies have shown that crude extracts and compounds isolated from AC possess anti-inflammatory effects in different cell types [21, 22, 34, 60]. In parallel, our data demonstrate that HPAC reduces inflammatory responses in LPS-activated macrophage cells. The secretion of proinflammatory cytokines, including TNF-α, IL-6, and IL-1β, were inhibited by HPAC treatment (Figures 2(b)–2(d)). In order to identify the potential mechanism of action, we analyzed the NF-κB pathway. NF-κB is a well-characterized transcriptional regulator responsible for promoting the production of inflammatory mediators [37, 38]. The activation of NF-κB is accompanied by IκB phosphorylation and degradation, leading to NF-κB nuclear translocation [61, 62]. HPAC significantly attenuated the nuclear translocation of NF-κB p65 through coordinated regulation of IκBα phosphorylation (Figures 3(a)–3(d)), which perhaps explains the decrease in IL-6, IL-1β, and TNF-α production (Figures 2(b)–2(d)).

In addition, NF-κB is a pivotal transcription factor that regulates the expression of iNOS and COX-2 enzymes [42]. The excessive production of iNOS-derived NO can act as modulators of inflammation [42]. HPAC significantly diminished the iNOS and NO levels in LPS stimulated RAW 264.7 cells (Figures 4(a)–4(c)). However, the HPAC-
Figure 5: Effects of HPAC on HO-1 via MAPK signaling. RAW 264.7 cells were treated with HPAC 200 μg/mL for indicated times. 
(a) Western blot analysis of HO-1 and β-actin. (b) Quantitative analysis of HO-1 expression relative to β-actin. RAW 264.7 cells were treated with indicated concentration of HPAC for 4 h. (c) Western blot analysis of HO-1, p-p38, p38, p-ERK, ERK, p-JNK, JNK, and β-actin. Quantitative analysis of (d) HO-1 expression relative to β-actin, (e) p-p38 expression relative to p38, (f) p-ERK expression relative to ERK, and (g) p-JNK expression relative to JNK. RAW 264.7 cells were pretreated with specific MAPK inhibitors, SB203580 (20 μM), PD98059 (30 μM), and SP600125 (20 μM), for 1 h and then HPAC 200 μg/mL for 4 h. (h) Western blot analysis of HO-1 and β-actin. (i) Quantitative analysis of HO-1 expression relative to β-actin. The data are presented as means ± SEM (n = 3). *** p < 0.001 versus control group, * p < 0.05, ** p < 0.01, and *** p < 0.001 versus HPAC group.
mediated downregulation of NF-κB did not correlate with COX-2-dependent PGE2 synthesis (Figures 4(a)–4(g)). Earlier reports demonstrated that AC and its constituents inhibit the expression of COX-2 and PGE2 in cooperation with NF-κB suppression [31, 63, 64]. In light of this controversial observation, we investigated other enzymes regulating the synthesis (mPGES-1) and catabolism (15-PGDH) of PGE2. HPAC showed no effect on mPGES-1 expression (Figure 4(e)). Interestingly, HPAC ameliorated the LPS-induced decrease of 15-PGDH (Figure 4(f)). 15-PGDH rapidly oxidizes 15-(S)-hydroxyl group of PGE2 and leads to its degradation [45]. Our data suggest that HPAC potentiates reduction of proinflammatory lipid mediator PGE2 by 15-PGDH-dependent and COX-2/mPGES-1-independent manner. Several studies have reported agents that regulate the tumor-suppressing role of 15-PGDH. Cancer cell lines treated with indomethacin, TGF-β1, calcitriol, and histone deacetylases inhibitors activated the 15-PGDH transcription rates and induced antiproliferative effects [65–68]. One report demonstrates that 15-PGDH is activated by IL-4 in association with JAK/STAT6, MAPK, PI3K, and PKC signaling in lung cancer cells [69]. Recent reports suggest that 15-PGDH is modulated by microRNAs (miRNA). In many types of tumors, miRNA-21 binds to the 3’-UTR site of 15-PGDH mRNA and inhibits 15-PGDH expression, which in turn promotes tumor growth [70–73]. In cervical cancer, miR-146b-3p negatively regulated 15-PGDH involving STAT3 and AKT signaling [74]. One study demonstrates that tumor radioresistance is mediated by miR-620 targeting 15-PGDH [75]. Further research is needed to fully understand how HPAC regulates 15-PGDH.

HO-1 has been reported to negatively regulate NF-κB and inhibit the production of proinflammatory mediators [50, 51]. Multiple mechanisms have been reported to induce the expression of HO-1, including MAPK pathway [47–49]. Since HPAC elevated HO-1 expression in a time- and dose-dependent manner, the association between HO-1 and MAPK pathway was examined. HPAC induced the phosphorylation of p38, ERK, and JNK in parallel with HO-1 expression (Figures 5(c)–5(g)). Moreover, we also determined the effect of specific MAPK inhibitors on HPAC-induced HO-1. Our experiment shows that all three inhibitors (SB203580, PD98059, and SP600125) significantly reversed the HO-1 increase by HPAC. Our data confirm that MAPK signaling is involved in HPAC-mediated regulation of HO-1 (Figures 5(h) and 5(i)). Based on the inhibitory effects of HPAC on LPS-induced NF-κB activation, we asked whether HO-1 was linked to these effects. Our results show that HO-1 was effectively increased, whereas phosphorylated IκBα was markedly decreased by HPAC in LPS-treated cells (Figures 6(a)–6(c)). Previous studies have shown that blocking HO-1 restored IκBα phosphorylation and NF-κB nuclear translocation, thereby interfering with the anti-inflammatory effect of chlorogenic acid and lycopene [76, 77].
To further verify the effect of HO-1 on the crosstalk between MAPK pathway and NF-kB pathway, we blocked the HO-1 activity using specific MAPK inhibitors. Despite the fact that all three inhibitors blocked HO-1 activity in HPAC-treated RAW 264.7 cells, the MAPK inhibitors vary in their effect to reverse the expression of HO-1 induced by HPAC in LPS-challenged cells. Both SB203580 and SP600125 achieved HO-1 downregulation and nuclear NF-kB p65 upregulation; however, PD98059 showed no effect (Figures 6(a)–6(e)). Although HO-1 was suppressed, SP600125 was not sufficient to induce phosphorylation-induced degradation of IkBa compared to SB203580 (Figures 6(a)–6(c)). Interestingly, one study suggests crosstalk between JNK and NF-kB pathway in TNF-α-stimulated HepG2 cells [78]. The JNK inhibitor SP600125 reduced HSP27 phosphorylation, which plays a crucial role in the binding ability of IKK with IkBα [78]. It may be possible that SP600125 interfered with IkBα phosphorylation. Even though IkBα phosphorylation and degradation are impaired by JNK inhibition, the increased NF-kB nuclear translocation remains unclear. Nonetheless, only the p38/HO-1 signaling pathway seems to be required for phosphorylation and degradation of IkBα. Our results indicate the importance of p38/HO-1 signaling pathway for HPAC-mediated regulation on IkBα/NF-κB complex under LPS inflammatory condition.

5. Conclusions

AC has been widely consumed as a dietary product in Asia. Since heat processing is used to promote drug effectiveness and safety in herbal medicine, we provide evidence that HPAC decreases inflammatory responses. Previous studies have shown that pure capillarisin (CAP) isolated from AC aerial parts of AC and some of its coumarin and flavonoid derivatives show anti-inflammatory activity via 5-lipoxygenase (LOX) inhibition [80]. Interestingly in this study, inhibition of PGE2 secretion was mediated through 15-PGDH upregulation and not through COX-2 inhibition. Regulatory effects of HPAC on IkBα/NF-kB complex and 15-PGDH may explain the anti-inflammatory activity and HPAC may serve as a candidate for developing anti-inflammatory agents.

There have been reports to achieve optimal extraction temperatures for enhancing HPAC anti-inflammatory capacity [81]. Further in vivo studies and experiments regarding heat processing conditions may help better understand the (drug) mechanism of HPAC and aid its development as an anti-inflammatory agent.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All authors have read and agreed to the published version of the manuscript. Akhtar Ali and Wonnam Kim conceptualized the study; Akhtar Ali, Junsik Lim, and Jong-Hyun Lee performed investigation; Shin Seong was responsible for resources; Akhtar Ali, Jong-Hyun Lee, and Wonnam Kim prepared the original draft; En Hyung Kim and Wonnam Kim reviewed and edited the manuscript; Shin Seong and Wonnam Kim performed study supervision; and Wonnam Kim was involved in funding acquisition.

Supplementary Materials

Supplementary Figure 1: the cytotoxicity of the AC on RAW 264.7 cells. (Supplementary Materials)

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (no. NRF-2018R1C1B6002803).

References

[1] F. Berenbaum, “Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation,” Joint Bone Spine, vol. 67, no. 6, pp. 561–564, 2000.
[2] A. Minagar, P. Shapshak, R. Fujimura, R. Ownby, M. Heyes, and C. Eisdorfer, “The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis,” Journal of the Neurological Sciences, vol. 202, no. 1-2, pp. 13–23, 2002.
[3] R. Medzhitov, “Inflammation 2010: new adventures of an old flame,” Cell, vol. 140, no. 6, pp. 771–776, 2010.
[4] C. Nathan and A. Ding, “Nonresolving inflammation,” Cell, vol. 140, no. 6, pp. 871–882, 2010.
[5] M. A. Islam, F. Alam, M. Solayman, M. I. Khalil, M. A. Kamal, and S. H. Gan, “Dietary phytochemicals: natural swords combating inflammation and oxidation-mediated degenerative diseases,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5137431, 25 pages, 2016.
[6] B. Hosseini, B. S. Berthlon, A. Saedisomeolia et al., “Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: a systematic literature review and meta-analysis,” The American Journal of Clinical Nutrition, vol. 108, no. 1, pp. 136–155, 2018.
[7] A. M. Zivkovic, N. Telis, J. B. German, and B. D. Hammock, “Dietary omega-3 fatty acids aid in the modulation of inflammation and metabolic health,” California Agriculture, vol. 65, no. 3, pp. 106–111, 2011.
[8] J. S. Jurenka, “Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research,” Alternative Medicine Review: A Journal of Clinical Therapeutic, vol. 14, no. 2, pp. 141–153, 2009.
Evidence-Based Complementary and Alternative Medicine 11

[9] R. D. Altman and K. C. Marcussen, “Effects of a ginger extract on knee pain in patients with osteoarthritis,” Arthritis & Rheumatism, vol. 44, no. 11, pp. 2531–2538, 2001.

[10] A. Mondal, T. K. Maity, and A. Bishaye, “Analgescic and anti-inflammatory activities of quercetin-3-methoxy-4’-glucosyl-7-glucoside isolated from Indian medicinal plant melothria heterophylla,” Medicines (Basel, Switzerland), vol. 6, no. 2, 2019.

[11] G. O. De Melo, D. d. C. Malvar, F. A. Vanderlinde et al., “Antinociceptive and anti-inflammatory kaempferol glycosides from Sedum dendroideum,” Journal of Ethnopharmacology, vol. 124, no. 2, pp. 228–232, 2009.

[12] K. S. Bora and A. Sharma, “Genus Artemisia: a comprehensive review,” Pharmaceutical Biology, vol. 49, no. 1, pp. 101–109, 2011.

[13] M. J. Abad, L. M. Bedoya, L. Apaza, and P. Bermejo, “Genus: a review of bioactive essential oils,” Molecules, vol. 17, no. 3, pp. 2542–2566, 2012.

[14] E. A. Brisibe, U. E. Unoren, F. Brisibe et al., “Nutritional characterisation and antioxidant capacity of different tissues of Artemisia annua L,” Food Chemistry, vol. 115, no. 4, pp. 1240–1246, 2009.

[15] M. J. Abad, L. M. Bedoya, L. Apaza, and P. Bermejo, “The Genus Artemisia: a review of bioactive essential oils,” Molecules, vol. 17, no. 3, pp. 2542–2566, 2012.

[16] E. Jang, M.-H. Shin, K.-S. Kim et al., “Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, p. 253, 2014.

[17] J. Lee, K. Chae, J. Ha et al., “Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaris in high-fat diet-induced obese mice,” Journal of Ethnopharmacology, vol. 115, no. 2, pp. 263–270, 2008.

[18] J. Pan, G. Liu, H. Liu, Z. Qiu, and L. Chen, “[Effects of artemisia capillaris on blood glucose and lipid in mice],” Zhong Yao Cai = Zhongyaozai = Journal of Chinese Medicinal Materials, vol. 21, no. 8, pp. 408–411, 1998.

[19] H. Yan, K. H. Jung, J. Kim, M. Rumman, M. S. Oh, and S.-S. Hong, “Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway,” Biomedicine & Pharmacotherapy, vol. 98, pp. 134–141, 2018.

[20] H.-C. Seo, M. Suzuki, M. Ohnishi-Kameyama et al., “Extraction and identification of antioxidant components from Artemisia capillaris herba,” Plant Foods for Human Nutrition, vol. 58, no. 3, pp. 1–12, 2003.

[21] S. J. Hwang, Y.-W. Kim, Y. Park, H.-J. Lee, and K.-W. Kim, “Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells,” Inflammation Research, vol. 63, no. 1, pp. 81–90, 2014.

[22] D. Y. Cho, H. M. Ko, J. Kim et al., “Scoparone inhibits LPS-simulated inflammatory response by suppressing IRF3 and ERK in BV-2 microglial cells,” Molecules (Basel, Switzerland), vol. 21, no. 12, 2016.

[23] A. Serino and G. Salazar, “Protective role of polyphenols against vascular inflammation, aging and cardiovascular disease,” Nutrients, vol. 11, no. 1, 2018.

[24] P. Li, Y.-L. Yin, D. Li, S. Woo Kim, and G. Wu, “Amino acids and immune function,” British Journal of Nutrition, vol. 98, no. 2, pp. 237–252, 2007.

[25] H. H. Yoo, J. H. Park, and S. W. Kwon, “In vitro cytotoxic activity of some Korean medicinal plants on human cancer cell lines: enhancement in cytotoxicity by heat processing,” Phytotherapy Research, vol. 21, no. 9, pp. 900–903, 2007.

[26] C. Z. Wang, H. H. Aung, B Zhang et al., “Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells,” Anticancer Research, vol. 28, no. 5A, pp. 2545–2551, 2008.

[27] K. S. Kang, J. Ham, Y.-J. Kim, J. H. Park, E.-J. Cho, and N. Yamabe, “Heat-processed Panax ginseng and diabetic renal damage: active components and action mechanism,” Journal of Ginseng Research, vol. 37, no. 4, pp. 379–388, 2013.

[28] M.-S. Lee, C.-J. Chen, L. Wan et al., “Quercetin is increased in heat-processed Cuscuta campestris seeds, which enhances the seed’s anti-inflammatory and anti-proliferative activities,” Process Biochemistry, vol. 46, no. 12, pp. 2248–2254, 2011.

[29] T. Su, B. C.-Y. Cheng, X.-Q. Fu et al., “Comparison of the toxicities, bioactivities and chemical profiles of raw and processed Xanthii Fructus,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, p. 24, 2016.

[30] L. Hui-min, “A549 cell inhibitory activity from heat-processed Gynostemma pentaphyllum,” Journal of Minzu University of China, vol. 21, pp. 49–53, 2012.

[31] H. S. Kim, E. J. Park, Y. M. Kim et al., “Heme oxygenase-1 induction through p38 MAPK/Nrf2 activation by ethanol extract of Artemisia capillaries inhibits LPS-activated iNOS, COX-2, and HMGB1 in RAW 264.7 cells,” Phytopharmacology, vol. 4, no. 3, pp. 468–480, 2013.

[32] J. C. Ryu, S. M. Park, M. Hwangbo et al., “Methanol extract of artemisia apiaceae hance attenuates the expression of inflammatory mediators via NF- kappa B inactivation,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 494681, 12 pages, 2013.

[33] S. M. Kim, P. Vetreliv, H. H. Kim, S. E. Ha, V. V. G. Saralamma, and G. S. Kim, “Artemisia iwayomogi (Dowijigi) inhibits lipopolysaccharide-induced inflammation in RAW264.7 macrophages by suppressing the NF-kappaB signaling pathway,” Experimental and Therapeutic Medicine, vol. 19, no. 3, pp. 2161–2170, 2020.

[34] S. Hong, S. Seo, J. Lee, and B. Choi, “The aqueous extract from Artemisia capillaris Thunb. inhibits lipopolysaccharide-induced inflammatory response through preventing NF-κB activation in human hepatoma cell line and rat liver,” International Journal of Molecular Medicine, vol. 13, no. 5, pp. 717–720, 2004.

[35] S. Shin, Y. Shin, J. Lee et al., “Ethanol-heated processed scutellariae radix improve inflammatory response through an inhibitory effect against oxidative stress in mice with the lipopolysaccharide-induced intestine injury of mice,” The Korea Journal of Herbalogy, vol. 30, no. 4, pp. 81–88, 2015.

[36] N. Bordag, S. Klie, K. Jürchott et al., “Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects,” Scientific Reports, vol. 5, no. 1, p. 15954, 2015.

[37] R. G. Baker, M. S. Hayden, and S. Ghosh, “NF-κB, inflammation, and metabolic disease,” Cell Metabolism, vol. 21, no. 1, pp. 11–22, 2011.

[38] P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 7–11, 2001.

[39] E. Mathes, E. L. O’Dea, A. Hoffmann, and G. Ghosh, “NF-κB dictates the degradation pathway of IκB,” The EMBO Journal, vol. 27, no. 9, pp. 1357–1367, 2008.

[40] J. N. Sharma, A. Al-Omran, and S. S. Parvathy, “Role of nitric oxide in inflammatory diseases,” Inflammopharmacology, vol. 15, no. 6, pp. 252–259, 2007.
Evidence-Based Complementary and Alternative Medicine

[41] S. B. Abramson, “Nitric oxide in inflammation and pain associated with osteoarthritis,” *Arthritis Res Ther*, vol. 10, no. S2, p. S2, 2008.

[42] F. Aktan, “iNOS-mediated nitric oxide production and its regulation,” *Life Sciences*, vol. 75, no. 6, pp. 639–653, 2004.

[43] D. S. Chi, M. Qui, G. Krishnaswamy, C. Li, and W. Stone, “Regulation of nitric oxide production from macrophages by lipopolysaccharide and catecholamines,” *Nitric Oxide*, vol. 8, no. 2, pp. 127–132, 2003.

[44] K. Kawahara, H. Hohjoh, T. Inazumi, S. Tsuchiya, and Y. Sugimoto, “Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors,” *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, vol. 1851, no. 4, pp. 414–421, 2015.

[45] A. I. Ivanov and A. A. Romanovsky, “Prostaglandin E2 as a mediator of fever: synthesis and catabolism,” *Frontiers in Bioscience*, vol. 9, no. 1–3, pp. 1977–1993, 2004.

[46] H.-O. Pae and H.-T. Chung, “Heme oxygenase-1: its therapeutic roles in inflammatory diseases,” *Immune Network*, vol. 9, no. 1, pp. 12–19, 2009.

[47] E. J. Park, Y. M. Kim, S. W. Park et al., “Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of *Inula helenium* L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice,” *Food and Chemical Toxicology*, vol. 55, pp. 386–395, 2013.

[48] E. J. Park, Y. M. Kim, H. J. Kim, and K. C. Chang, “Luteolin activates ERK1/2- and Ca2+-dependent HO-1 induction that reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expression in RAW264.7 cells and mitigates acute lung injury of endotoxin mice,” *Inflammation Research*, vol. 67, no. 5, pp. 445–453, 2018.

[49] T. Kietzmann, A. Samoylenko, and S. Immenschuh, “Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes,” *Journal of Biological Chemistry*, vol. 278, no. 20, pp. 17927–17936, 2003.

[50] D.-S. Lee, K.-S. Kim, W. Ko et al., “The neoflavonoid latifolin isolated from MeOH extract of *Dalbergia odorifera* Attenuates inflammatory responses by inhibiting NF-κB Activation via Nrf2-mediated heme oxygenase-1 expression,” *Phytotherapy Research*, vol. 28, no. 8, pp. 1216–1223, 2014.

[51] L. Jiang, Q. Jiang, S. Yang et al., “GY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation,” *Pulmonary Pharmacology & Therapeutics*, vol. 54, pp. 77–86, 2019.

[52] S. Y. Pan, G. Litscher, S. H. Gao et al., “Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal Resources,” *Evidence-based Complementary and Alternative Medicine: ECAM*, vol. 2014, Article ID 525340, 20 pages, 2014.

[53] X. Wu, S. Wang, J. Lu et al., “Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives,” *Chinese Medicine*, vol. 13, no. 1, p. 4, 2018.

[54] I. An, S. C. Kim, S. H. Byun, J. R. Lee, and S. J. Park, “Anti-inflammatory effect of the processed gardeniae fructus in LPS-induced macrophages,” *Herbal Formula Science*, vol. 27, no. 4, pp. 245–255, 2019.

[55] S. Kany, J. T. Vollrath, and B. Relja, “Cytokines in inflammatory disease,” *International Journal of Molecular Sciences*, vol. 20, no. 23, 2019.

[56] W. Strober and I. J. Fuss, “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases,” *Gastroenterology*, vol. 140, no. 6, pp. 1756–1767, 2011.

[57] S. C. Mejivis, H. Hardeman, H. H. Remmeleits et al., “Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial,” *The Lancet*, vol. 377, no. 9782, pp. 2023–2030, 2011.

[58] M. Marini, E. Vittori, J. Hollembrg, and S. Mattoli, “Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma,” *Journal of Allergy and Clinical Immunology*, vol. 89, no. 5, pp. 1081–1089, 1992.

[59] A. Linde, D. Mosier, F. Blecha, and T. Meltgereoj, “Innate immunity and inflammation—new frontiers in comparative cardiovascular pathology,” *Cardiovascular Research*, vol. 73, no. 1, pp. 26–36, 2007.

[60] H.-K. Lim, “Inhibitory effects of an ethanol extract of *Artemisia capillaris* on inflammatory mediators from LPS-stimulated RAW 264.7 cells,” *Journal of the Korean Society for Applied Biological Chemistry*, vol. 53, no. 3, pp. 275–282, 2010.

[61] M. Karin and Y. Ben-Neriah, “Phosphorylation meets ubiquitination: the control of NF-κB activity,” *Annual Review of Immunology*, vol. 18, no. 1, pp. 621–663, 2000.

[62] M. W. Covert, T. H. Leung, J. E. Gaston, and D. Baltimore, “Achieving stability of lipopolysaccharide-induced NF-κB activation,” *Science*, vol. 309, no. 5742, pp. 1854–1857, 2005.

[63] S. Han, J. H. Lee, C. Kim et al., “Capillarine inhibits iNOS, COX-2 expression, and proinflammatory cytokines in LPS-induced RAW 264.7 macrophages via the suppression of ERK, JNK, and NF-κB activation,” *Immunopharmacology and Immunotoxicology*, vol. 35, no. 1, pp. 34–42, 2013.

[64] J.-D. Cha, S.-E. Moon, H.-Y. Kim, J.-C. Lee, and K.-Y. Lee, “The essential oil isolated from *Artemisia capillaris* Prevents LPS-induced production of NO and PGE2 by inhibiting MAPK-mediated pathways in RAW 264.7 macrophages,” *Immunological Investigations*, vol. 38, no. 6, pp. 483–497, 2009.

[65] M. Tong, Y. Ding, and H.-H. Tai, “Histone deacetylase inhibitors and transforming growth factor-β induces 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells,” *Biochemical Pharmacology*, vol. 72, no. 6, pp. 701–709, 2006.

[66] J. Moreno, A. V. Krishnan, S. Swami, L. Nonn, D. M. Peehl, and D. Feldman, “Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells,” *Cancer Research*, vol. 65, no. 17, pp. 7917–7925, 2005.

[67] M. Yan, R. M. Rerko, P. Platter et al., “15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers,” *Proceedings of the National Academy of Sciences*, vol. 101, no. 50, pp. 17468–17473, 2004.

[68] M. Frenkian, N. Segond, E. Pidoux, R. Cohen, and A. Jullienne, “Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation,” *Prostaglandins & Other Lipid Mediators*, vol. 65, no. 1, pp. 11–20, 2001.

[69] X. Chi and H.-H. Tai, “Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells,” *Experimental Cell Research*, vol. 316, no. 14, pp. 2251–2259, 2010.

[70] N. J. Monteleone, A. E. Moore, J. R. Iacona, C. S. Lutz, and D. A. Dixon, “miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer,” *Scientific Reports*, vol. 9, no. 1, p. 5405, 2019.
Y. S. Park, J. H. Lee, D.-B. Jung et al., “MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma,” *Scientific Reports*, vol. 8, no. 1, p. 17717, 2018.

L. Li, X. Wang, W. Li et al., “miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH,” *Biochemical and Biophysical Research Communications*, vol. 495, no. 1, pp. 928–934, 2018.

L. Lu, K. Byrnes, C. Han, Y. Wang, and T. Wu, “miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth,” *Molecular Cancer Research*, vol. 12, no. 6, pp. 890–900, 2014.

S. Yao, J. Xu, K. Zhao et al., “Down-regulation of HPGD by miR-146b-3p promotes cervical cancer cell proliferation, migration and anchorage-independent growth through activation of STAT3 and AKT pathways,” *Cell Death & Disease*, vol. 9, no. 11, p. 1055, 2018.

X. Huang, S. Taeb, S. Jahangiri et al., “miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD),” *Oncotarget*, vol. 6, no. 26, pp. 22439–22451, 2015.

L. Bao, J. Li, D. Zha et al., “Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-κB pathways,” *International Immunopharmacology*, vol. 54, pp. 245–253, 2018.

P.-M. Yang, H.-Z. Chen, Y.-T. Huang, C.-W. Hsieh, and B.-S. Wung, “Lycopene inhibits NF-κB activation and adhesion molecule expression through Nrf2-mediated heme oxygenase-1 in endothelial cells,” *International Journal of Molecular Medicine*, vol. 39, no. 6, pp. 1533–1540, 2017.

J. Ruan, Z. Qi, L. Shen et al., “Crosstalk between JNK and NF-κB signaling pathways via HSP27 phosphorylation in HepG2 cells,” *Biochemical and Biophysical Research Communications*, vol. 456, no. 1, pp. 122–128, 2015.

M. Kim, J. Chun, H. A. Jung, J. S. Choi, and Y. S. Kim, “Capillarisin attenuates exercise-induced muscle damage through MAPK and NF-κB signaling,” *Phytotherapy Research*, vol. 32, pp. 30–36, 2017.

O. S. Kwon, J. S. Choi, M. N. Islam, Y. S. Kim, and H. P. Kim, “Inhibition of 5-lipoxygenase and skin inflammation by the aerial parts of Artemisia capillaris and its constituents,” *Archives of Pharmacal Research*, vol. 34, no. 9, pp. 1561–1569, 2011.

M. Jang, S. W. Jeong, B. K. Kim, and J. C. Kim, "Extraction optimization for obtaining Artemisia capillaris extract with high anti-inflammatory activity in RAW 264.7 macrophage cells," *BioMed Research International*, vol. 2015, Article ID 872718, 9 pages, 2015.